ABPI response to Lord O'Shaughnessy Review

20 February 2023 Posted in News by Press Office

The Office for Life Sciences has today announced that Lord James O’Shaughnessy will conduct a review of the UK's commercial clinical trials landscape.

The review will offer recommendations on how commercial clinical trials can help the life sciences sector unlock UK growth and investment opportunities and advise on how to resolve key challenges in conducting commercial clinical trials in the UK. 

The ABPI will work closely with our members and Lord O’Shaughnessy to provide practical solutions on how we can deliver the systemwide reform needed to rebuild our global competitiveness and support NHS patients. Dr Jennifer Harris, ABPI Director of Research Policy

In response, the ABPI's Director of Research Policy Dr Jennifer Harris said: 

“Addressing the worrying decline of industry-sponsored clinical research in the NHS is critical if we are to deliver the UK’s ambitions for the life sciences sector and to support NHS recovery.

“The appointment of Lord O’Shaughnessy to carry out this review is an important recognition that we need to act decisively to reverse this negative trend.

“The ABPI will work closely with our members and Lord O’Shaughnessy to provide practical solutions on how we can deliver the system-wide reform needed to rebuild our global competitiveness and support NHS patients.”

TAGS
  • Clinical research

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​